Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Journal of Neuro-Oncology, 07/02/09
Wen PY et al. - Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted.
Related Articles
A meningioma of the scalp that might have developed from a rudimentary meningocele
Clinical and Experimental Dermatology, 10/16/09
Relevance Score: 90%
Jugular fossa meningioma: Presentation and treatment options
ENT Journal, 10/21/09
Relevance Score: 89%
Diagnosis and Treatment of the Primary Malignant Meningioma in Mediastinum: A Case Report
Southern Medical Journal, 11/10/09
Relevance Score: 88%
Radiation-induced meningiomas: A shadow in the success story of childhood leukemia
Neuro-Oncology, 10/06/09
Relevance Score: 88%
Does protein expression predict recurrence of benign World Health Organization grade I meningioma
Human Pathology, 10/08/09
Relevance Score: 87%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiosurgery and whole brain therapy in the treatment of brainstem metastases
Clinical and Translational Oncology, 11/25/09
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2
Virchows Archiv, 11/25/09
Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines
Pediatric Hematology and Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


